RT Journal Article
SR Electronic
T1 Incidence Rates of Medically Attended COVID-19 in Infants Less than 6 Months of Age
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.28.22280464
DO 10.1101/2022.09.28.22280464
A1 Griffin, Isabel
A1 Irving, Stephanie A.
A1 Arriola, Carmen Sofia
A1 Campbell, Angela P.
A1 Li, De-Kun
A1 Dawood, Fatimah S.
A1 Doughty-Skierski, Caroline
A1 Ferber, Jeannette R.
A1 Ferguson, Nickolas
A1 Hadden, Louise
A1 Henderson, Jillian T.
A1 Juergens, Mary
A1 Kancharla, Venkatesh
A1 Naleway, Allison L.
A1 Newes-Adeyi, Gabriella
A1 Nicholson, Erin
A1 Odouli, Roxana
A1 Reichle, Lawrence
A1 Sanyang, Mo
A1 Woodworth, Kate
A1 Munoz, Flor M.
YR 2022
UL http://medrxiv.org/content/early/2022/09/30/2022.09.28.22280464.abstract
AB Objective Studies suggest infants may be at increased risk of severe COVID-19 relative to older children, but few data exist regarding the incidence of COVID-19 episodes and associated risk factors. We estimate incidence rates and describe characteristics associated with medically attended COVID-19 episodes among infants younger than 6 months of age.Methods We analyzed electronic medical record data from a cohort of infants born March 1, 2020‒ February 28, 2021. Data from three health care delivery systems included demographic characteristics, maternal and infant outpatient visit and hospitalization diagnoses, and SARS-CoV-2 test results. Medically attended COVID-19 episodes were defined by positive SARS-CoV-2 clinical tests and/or COVID-19 diagnosis codes during medical care visits. Unadjusted and site-adjusted incidence rates by infant month of age, low and high SARS-CoV-2 circulation periods and maternal COVID-19 diagnosis were calculated.Results Among 18,192 infants aged <6 months whose mothers received prenatal care within the three systems, 173 (1.0%) had medically attended COVID-19 episodes. Incidence rates were highest among infants aged under 1 month (2.0 per 1,000 person-weeks) and 1 month (2.0 per 1,000 person-weeks) compared with older infants. Incidence rates were also higher for infants born to women with postpartum COVID-19 compared with women without known COVID-19 and women diagnosed with COVID-19 during pregnancy.Conclusion Most medically attended COVID-19 episodes in infants aged <6 months were outpatient care encounters. Infants of women with postpartum COVID-19 had a higher risk of medically attended COVID-19 than infants born to mothers who were diagnosed during pregnancy or never diagnosed underscoring the importance of COVID-19 prevention measures for their household members and caregivers to prevent infections in infants.Article Summary This report describes incidence rates and characteristics of medically attended outpatient and inpatient COVID-19 episodes among infants aged <6 months during the COVID-19 pandemic.What’s Known on This Subject Surveillance data and case series suggest that infants aged <1 year may be more likely to be hospitalized with COVID-19 than older children, but few data are available about the risk of medically attended COVID-19 episodes among infants.What this Study Adds Among infants aged <6 months, few were hospitalized with COVID-19. Incidence rates of medically attended COVID-19 episodes were highest among infants aged ≤ 1 month and among infants of women with COVID-19 during the 6 month post-partum period.Competing Interest StatementConflict of Interest Disclosures (includes financial disclosures): Author A. Naleway reports institutional support from Pfizer and Vir Biotechnology. All other authors have indicated that they have no conflicts of interest or financial relationships relevant to this article to disclose. Other Disclosures: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Funding StatementFunding/Support: This study was funded by the US Centers for Disease Control and Prevention (CDC) through Contract # 75D30120C08150 with Abt Associates. Role of Funder/Sponsor: This study was funded by the US Centers for Disease Control and Prevention (CDC). CDC-affiliated authors were involved in study design, data collection, analysis and interpretation, report writing, and the decision to submit the paper for publication. The corresponding author had full access to all data used in the analysis and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was reviewed by the Institutional Review Boards of participating sites (Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; Kaiser Permanente Northern California, Oakland, California; Baylor College of Medicine, Houston, Texas). Sites gave ethical approval for this work. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All data produced in the present study are available upon reasonable request to the authors. COVID-19coronavirus disease 2019,SARS-CoV-2severe acute respiratory syndrome coronavirus 2,RT-PCRReverse Transcription Polymerase Chain Reaction.